For the estimated 39 million people living with HIV globally — many now reaching older age thanks to antiretroviral therapy — the elevated risk of Alzheimer's-like dementia has long been observed clinically but mechanistically poorly understood. A new preclinical model now offers a window into how these two devastating conditions may compound each other at the cellular and molecular level.
Researchers engineered a humanized mouse line — designated hNAIL — combining the Swedish APP knock-in mutation (KM670/671NL), a well-validated Alzheimer's genetic driver, with an immunocompromised NOG background reconstituted with human CD34+ hematopoietic stem cells. The resulting animals develop human microglia-like cells in the brain alongside a peripheral human immune system, enabling, for the first time, active HIV-1 brain replication within an Alzheimer's-susceptible neurological environment. Infection with the HIV-1 ADA strain at four months of age and assessment at eight weeks post-infection revealed that viral replication measurably increased amyloid-beta (Aβ) plaque burden and degraded synaptic and neuronal integrity beyond what either condition produced alone. Cell-type-resolved spatial transcriptomics showed that Aβ pathology and HIV-1 each drive distinct gene-expression signatures, but their co-occurrence produced an amplified, synergistic transcriptional state — concentrated most heavily in neurons — implicating neuroinflammation, protein trafficking disruption, and synaptic dysfunction as convergent mechanisms.
This work is genuinely platform-building rather than hypothesis-confirming. The hNAIL model addresses a longstanding gap: prior animal systems could model either HIV neurotropism or Alzheimer's amyloidogenesis, but not their interaction with humanized immune components. Limitations are substantial — this is an 8-week mouse study with no antiretroviral treatment arm, and the Swedish mutation represents a familial rather than sporadic AD genotype. The transcriptomic readouts, though spatially resolved, remain correlational. Still, by establishing a reproducible dual-pathology platform, this study positions future work to test whether specific antiretrovirals or neuroinflammatory interventions can decouple HIV-driven amyloid acceleration — a question with direct relevance for aging HIV-positive populations.